US 10,851,176 B2Granted

Methods of administering neutralizing anti-protease nexin-1 antibodies to treat hemophilia A

AssigneesInserm (Institut National De La Sante Et De La Recherche Medicale), Universite Paris Diderot—Paris 7, Université Paris Xiii Paris-Nord

InventorsMarie-Christine Bouton, Petrus Lenting, Cécile Denis, Olivier Christophe

Life of this patent

Estimating the term…

Abstract

The present invention relates to a method and compositions for the treatment of haemorrhagic diseases.

Claims4

Dependent claims

A method for treating mild or moderate haemophilia A in a subject in need thereof, comprising the step of administering to said subject a protease nexin-1 activity inhibitor, wherein the protease nexin-1 activity inhibitor is an anti-protease nexin-1 neutralizing antibody.

Dependencies are inferred from the claim text.

Facts

Application: 15/565,933Filed 12 Apr 2016
Priority: EP 1530554413 Apr 2015
Published: US 2018/0105603 A119 Apr 2018
Granted: 1 Dec 2020
Term ends: Not estimatedThe source records don’t support an estimate.

Classification16 codes

C07K 16/38
Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies: against protease inhibitors of peptide structure
A61K 31/7088
Carbohydrates; Sugars; Derivatives thereof: compounds having three or more nucleosides or nucleotides
A61K 31/713
Compounds having three or more nucleosides or nucleotides: double-stranded nucleic acids or oligonucleotides
A61K 38/363
Blood coagulation or fibrinolysis factors: fibrinogen

Family

US 2018/0105603 A1Pre-grant publication · published 19 Apr 2018
US 10,851,176 B2This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results